Psilocybin and psilocin research index

Select for export

Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.

IntroductionMajor depressive disorder remains a prevalent world-wide health problem. Currently available antidepressant medications take weeks of dosing, do not produce antidepressant response in all patients, and have undesirable ancillary effects.Areas coveredThe present opinion piece focuses on the major inroads to the creation of new antidepressants. The...

Details DOI 10.1080/17460441.2022.2111415 PubMed 35934973 Copy citation Copy BibTeX

Expert Opinion on Drug Discovery 2022-08-21 Pilc A, Machaczka A, Kawalec P, Smith JL, Witkin JM.

Europe PMC Published psilocybin DepressionPharmacologyMechanism of Action Animal Study Humans More

Select for export

Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.

Purpose of the reviewWe aim to provide an overview of the current state of knowledge about the efficacy of psilocybin in the treatment of depression, as well as its mechanisms of action.Recent findingsPsilocybin has a large, rapid, and persistent clinical effect in the treatment of resistant or end-of-life depression. Tolerance is good, with mild side effect...

Details DOI 10.1007/s11920-022-01361-0 PubMed 35953638 Copy citation Copy BibTeX

Unknown journal 2022-08-11 Prouzeau D, Conejero I, Voyvodic PL, Becamel C, Abbar M, Lopez-Castroman J.

Europe PMC Published psilocybin DepressionEnd-of-Life DistressMechanism of Action Clinical Trial Humans More

Select for export

Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.

Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence supports PAT as a novel therapeutic approach that provides safe and effective treatment for people suffering from a variety of diagnoses, including treatment-resistant depression, substance use disorder, and post...

Details DOI 10.1089/jpm.2022.0036 PubMed 35285721 Copy citation Copy BibTeX

Journal of palliative medicine 2022-07-31 Rosa WE, Sager Z, Miller M, Bernstein I, Doerner Rinaldi A, Addicott K

PubMed Published psilocybin DepressionAnxietyPTSD Other LSD More

Select for export

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

The primary aim of this study is to assess the safety and tolerability of one 25 mg dose of psilocybin in participants with anorexia nervosa based on adverse events (AEs), changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests. The secondary objectives are to explore the efficacy of a single 25 mg dose of psilocybin on eating disorde...

Details Copy citation Copy BibTeX

ClinicalTrials.gov 2022-07-24 University of California, San Diego

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyAddiction Clinical Trial Anorexia Nervosa More

Select for export

From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q)

Background: The Relaxed Beliefs Under pSychedelics (REBUS) model proposes that serotonergic psychedelics decrease the precision weighting of neurobiologically-encoded beliefs, and offers a unified account of the acute and therapeutic action of psychedelics. Although REBUS has received some neuroscientific support, little research has examined its psychologic...

Details DOI 10.31234/osf.io/w8j6t Copy citation Copy BibTeX

PsyArXiv 2022-07-06 Zeifman R, Spriggs MJ, Kettner H, Lyons T, Rosas F, Mediano P

PsyArXiv PREPRINT (not peer reviewed) psilocybin Brain ImagingMechanism of ActionWellbeing Other More

Select for export

From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q)

Background: The Relaxed Beliefs Under pSychedelics (REBUS) model proposes that serotonergic psychedelics decrease the precision weighting of neurobiologically-encoded beliefs, and offers a unified account of the acute and therapeutic action of psychedelics. Although REBUS has received some neuroscientific support, little research has examined its psychologic...

Details Copy citation Copy BibTeX

PsyArXiv 2022-07-06 Authors unavailable

PsyArXiv PREPRINT (not peer reviewed) psilocybin Brain ImagingPharmacologyMechanism of Action Other beliefs More

Select for export

Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults

To investigate the efficacy of a 16 week treatment with PSIL428 patient reported anxiety levels in otherwise healthy individuals suffering from depression and or anxiety symptoms. Randomized, double-blind, placebo-controlled study assessing the efficacy of micro-dosed psilocybin on reducing anxiety and/or depression levels in adults Study summary: The Instit...

Details Copy citation Copy BibTeX

ClinicalTrials.gov 2022-06-29 Wake Network, Inc.

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyWellbeing Clinical Trial Anxiety and Depression More

Select for export

Psychedelics as preventive treatment in headache and chronic pain disorders.

The effects of psychedelic drugs in headache and chronic pain disorders have been reported for several decades, and now controlled studies are emerging. The existing evidence supports a lasting therapeutic benefit after limited dosing, a unique feature of the drug class that distinguishes it from conventional treatment. This commentary summarizes these repor...

Details DOI 10.1016/j.neuropharm.2022.109166 PubMed 35718005 Copy citation Copy BibTeX

Unknown journal 2022-06-15 Schindler EAD.

Europe PMC Published psilocybin Chronic PainHeadache / MigraineMechanism of Action Review Article Humans More

Select for export

The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies.

The use of psilocybin as treatment for major depressive disorder (MDD) has been examined as a promising alternative to traditional first-line options. We reviewed existing literature to provide a synthesis of the extant neuroimaging observations with psilocybin, and to identify putative therapeutic targets for target engagement studies with psilocybin, and p...

Details DOI 10.1016/j.psychres.2022.114577 PubMed 35580433 Copy citation Copy BibTeX

Unknown journal 2022-04-25 Gill H, Puramat P, Patel P, Gill B, Marks CA, Rodrigues NB

Europe PMC Published psilocybin DepressionBrain ImagingAging Clinical Trial Amygdala More

Select for export

Will psilocybin lose its magic in the clinical setting?

Psilocybin as a novel treatment for depression is garnering a lot of attention from both the mainstream media and the academic community. Although phase 3 trials are only just beginning, we feel that it is important for clinicians to consider what psilocybin-assisted psychotherapy might look like in the clinical setting. In this narrative review article we h...

Details DOI 10.1177/20451253221090822 PubMed 35480296 Copy citation Copy BibTeX

Unknown journal 2022-04-21 Hayes C, Wahba M, Watson S.

Europe PMC Published psilocybin DepressionReview ArticleHealthcare Workers Clinical Trial More

Select for export

Psilocybin-Assisted Compassion Focused Therapy for Depression.

Psilocybin-assisted psychotherapy, i.e., psilocybin treatment with psychological support, has demonstrated the efficacy of psilocybin to reduce depressive symptoms. However, in clinical trials, the structure of psilocybin-assisted psychotherapy is primarily based on preparation, navigation (support during dosing sessions), and integration. For psychotherapeu...

Details DOI 10.3389/fpsyg.2022.812930 PubMed 35401294 Copy citation Copy BibTeX

Frontiers in Psychology 2022-03-24 Pots W, Chakhssi F.

Europe PMC Published psilocybin DepressionClinical Trial Clinical Trial More

Select for export

Demystifying Psychedelic Treatments in Psychiatry: Is Ego Dissolution the Solution?

Back to table of contents Previous article Next article Annual MeetingFull AccessDemystifying Psychedelic Treatments in Psychiatry: Is Ego Dissolution the Solution?Michael Avissar, M.D., Ph.D., Adrian Jacques Ambrose, M.D., M.P.H.Michael AvissarSearch for more papers by this author, M.D., Ph.D., Adrian Jacques AmbroseSearch for more papers by this author, M....

Details DOI 10.1176/appi.pn.2022.04.4.35 Copy citation Copy BibTeX

Psychiatric News 2022-03-23 Michael Avissar, Adrian Jacques H. Ambrose

OpenAlex Published psilocybin DepressionAnxietyPTSD Clinical Trial Psilocybin More

Select for export

Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.

Mushrooms have been used as traditional medicine for millennia, fungi are the main natural source of psychedelic compounds. There is now increasing interest in using fungal active compounds such as psychedelics for alleviating symptoms of mental health disorders including major depressive disorder, anxiety, and addiction. The anxiolytic, antidepressant and a...

Details DOI 10.3390/jof8030290 PubMed 35330292 Copy citation Copy BibTeX

Unknown journal 2022-03-10 Meade E, Hehir S, Rowan N, Garvey M.

Europe PMC Published psilocybin DepressionAnxietyAddiction Review Article More

Select for export

Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report.

Psychedelic drugs such as psilocybin have shown substantial promise for the treatment of several psychiatric conditions including mood and addictive disorders. They also have the remarkable property of producing persisting positive psychological changes in healthy volunteers for at least several months. In this study (NCT03289949), 35 medium-high doses of ps...

Details DOI 10.3389/fphar.2022.841648 PubMed 35355714 Copy citation Copy BibTeX

Frontiers in Pharmacology 2022-03-08 McCulloch DE, Grzywacz MZ, Madsen MK, Jensen PS, Ozenne B, Armand S

Europe PMC Published psilocybin Mystical ExperienceHealthy Volunteers Qualitative Study More

Select for export

Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice.

Serotonergic psychedelic drugs, such as psilocin (4-hydroxy-N,N-dimethyltryptamine), profoundly alter the quality of consciousness through mechanisms which are incompletely understood. Growing evidence suggests that a single psychedelic experience can positively impact long-term psychological well-being, with relevance for the treatment of psychiatric disord...

Details DOI 10.1038/s41398-022-01846-9 PubMed 35197453 Copy citation Copy BibTeX

Translational Psychiatry 2022-02-22 Thomas CW, Blanco-Duque C, Bréant BJ, Goodwin GM, Sharp T, Bannerman DM

Europe PMC Published psilocybinpsilocin DepressionNeuroplasticityBrain Imaging Animal Study Brain More

Select for export

Increased low-frequency brain responses to music after psilocybin therapy for depression

Psychedelic-assisted psychotherapy with psilocybin is an emerging therapy with great promise for depression, and modern psychedelic therapy (PT) methods incorporate music as a key element. Music is an effective emotional/hedonic stimulus that could also be useful in assessing changes in emotional responsiveness following psychedelic therapy. Brain responses ...

Details DOI 10.1101/2022.02.13.480302 Copy citation Copy BibTeX

bioRxiv 2022-02-14 Wall MB, Lam C, Ertl N, Kaelen M, Roseman L, Nutt DJ

bioRxiv PREPRINT (not peer reviewed) psilocybin DepressionBrain ImagingAging Other More

Select for export

Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review.

Psilocybin-containing mushrooms have been consumed by various cultures in many different parts of the world for thousands of years. Psilocybin, a classic psychedelic, contains unique psychoactive properties and has been incorporated into religious ceremonies and investigated for its medicinal value. In the mid-20th century, psilocybin, along with most other ...

Details DOI 10.7759/cureus.21944 PubMed 35273885 Copy citation Copy BibTeX

Unknown journal 2022-02-04 Ziff S, Stern B, Lewis G, Majeed M, Gorantla VR.

Europe PMC Published psilocybin DepressionAnxietyAddiction Clinical Trial More

Select for export

Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer

A49-year-old woman was diagnosed with an ER +, PR-, HER2 +, BRCA- invasive ductal carcinoma which progressed metastatically to include bone, liver, and lymph node involvement. Standardised care included a 26-month treatment period with targeted chemotherapy and a ketogenic diet. The patient also began a course of cannabinoid-based therapy, consisting initial...

Details DOI 10.1177/20503245221114323 Copy citation Copy BibTeX

Drug Science Policy and Law 2021-12-31 Rayyan Zafar, Dustin Sulak, Jaime Brambila, David Nutt, Anne Katrin Schlag

OpenAlex Published psilocybin End-of-Life DistressChronic PainPharmacology Other Medicine More

Select for export

Dosing Psychedelics and MDMA.

Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine, and mescaline, and entactogens/empathogens, especially 3,4-methylenedioxymethamphetamine, have received renewed attention in psychiatric research and may be developed into medications for such indications as anxiety, depression, cluster headache, and posttraumat...

Details DOI 10.1007/7854_2021_270 PubMed 34734392 Copy citation Copy BibTeX

Unknown journal 2021-12-31 Liechti ME, Holze F.

Europe PMC Published psilocybin DepressionAnxietyPTSD Other N-Methyl-3 More

Select for export

Psychedelics in the Treatment of Headache and Chronic Pain Disorders.

The therapeutic potential of psychedelics in headache and chronic pain disorders is documented over decades of anecdotal and early investigational reports, which have paved the way for the first controlled studies of psilocybin and lysergic acid diethylamide (LSD) in these disorders. The reported lasting clinical effects after limited dosing with psychedelic...

Details DOI 10.1007/7854_2022_365 PubMed 35546382 Copy citation Copy BibTeX

Unknown journal 2021-12-31 Schindler EAD.

Europe PMC Published psilocybin Chronic PainHeadache / MigraineReview Article Review Article Humans More